Paul has vast experience in inhaled product development across pharmaceutical and consumer products. He commenced his career working at a specialty pharmaceutical company where he gained experience of dry powder and metered dose inhaler development including treating local lung conditions and for systemic absorption for all stages of product development and commercial scale up. He also managed and successfully led the Quality Control department in a multinational pharmaceutical company that manufactured generic nicotine lozenges. Paul led the product characterisation team at Imperial Brands, where he designed the testing strategy for the chemistry of inhaled and oral next generation nicotine products assessing a variety of prototypes at the early stages of development and for regulatory submissions, including PMTA. He joined Broughton in 2021 as Head of Scientific Affairs and is responsible for consulting on and developing next generation nicotine product testing strategies for clients.